MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• MiNK Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from five brokerages, with a reported average 1-year price target of $37.50.
• The company's latest earnings report showed a loss of ($1.06) EPS, which missed analysts' expectations by ($0.51).
• As of the latest data, MiNK Therapeutics shares are trading at $14.90, with a market cap of $67.35 million, and a 52-week range of $4.56 to $76.00.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $37.50.

Several brokerages recently issued reports on INKT. Zacks Research cut MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, August 18th. Wall Street Zen cut MiNK Therapeutics to a "strong sell" rating in a report on Saturday. HC Wainwright upgraded MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price target on the stock in a research note on Friday, August 15th. William Blair cut shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. Finally, B. Riley raised shares of MiNK Therapeutics to a "strong-buy" rating in a research report on Friday, July 18th.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock traded down $0.33 during midday trading on Friday, reaching $14.57. The stock had a trading volume of 17,341 shares, compared to its average volume of 157,536. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00. The company has a fifty day moving average of $14.79 and a 200 day moving average of $10.43.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). Research analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.